Skip to NavigationSkip to content

FDA approves Novo Nordisk's Victoza for children with type 2 diabetes

Published on 18/06/19 at 09:03am

The FDA has approved Novo Nordisk’s Victoza (liraglutide) for paediatric patients aged 10 years and older with type 2 diabetes.

The drug is the first non-insulin drug approved to treat paediatric patients with type 2 diabetes since metformin was approved in 2000.

The injectable diabetes drug has however been available to adult patients since 2010.

Victoza, a glucagon-like peptide (GLP-1) receptor aganoist, works by creating the same effects as the GLP-1 receptor protein in the pancreas thus increasing insulin release from the pancreas and decreasing excessive glucagon release.

Dr Lisa Yanoff, acting director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research commented: “Victoza has now been shown to improve blood sugar control in paediatric patients with type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease.”

The drug was shown to be safe and effective in several placebo-controlled trials in adults and one placebo-controlled trial of 134 paediatric patients aged 10 and older.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches